Skip to main content
. 2020 May 4;9:e56655. doi: 10.7554/eLife.56655

Figure 1. Generation and validation of Pkd2 ecKO mice.

(A) Representative Western blots illustrating the effect of tamoxifen-treatment of Pkd2fl/fl and Pkd2fl/fl: Cdh5(PAC)-creERT2 mice on PKD2, PKD1, Piezo1, GPR68, eNOS, SK3, IK and TPRV4, proteins in mesenteric arteries. (B) Mean data for proteins in mesenteric arteries of tamoxifen-treated Pkd2fl/fl: Cdh5(PAC)-creERT2 mice when compared to those in tamoxifen-treated Pkd2fl/fl mice. n = 3–8. * indicates p<0.05 versus Pkd2fl/fl. (C) En-face immunofluorescence imaging illustrating that PKD2 protein (Alexa Fluor 555) is abolished in endothelial cells of mesenteric arteries in tamoxifen-treated Pkd2fl/fl: Cdh5(PAC)-creERT2 mice (representative of 6 mesenteric arteries). CD31 (Alexa Fluor 488) and DAPI are also shown. Scale bars = 50 µm.

Figure 1.

Figure 1—figure supplement 1. Genotyping of mouse lines.

Figure 1—figure supplement 1.

Genomic PCR indicating that tamoxifen (1 mg/ml, i.p., 3 days) stimulated Cre-recombination in mesenteric arteries of Pkd2fl/fl: Cdh5(PAC)-creERT2 mice. Representative of n = 3.